Open to all healthcare professionals / Donors / Recipients / Families
Steven Chadban, Paul Harden, Camille Kotton, Michael Ison, Ligia Pierotti
Open to all healthcare professionals
IPTA AHNP - PHTS WEBINAR - TUESDAY, APRIL 13, 2021 - 11:00AM EST (MONTREAL TIME)
This article reports findings in 23 patients who presented with thrombosis and thrombocytopenia 6 to 24 days after receiving the first dose of the ChAdOx1 nCoV-19 vaccine (AstraZeneca). In the absence of previous prothrombotic medical conditions, 22 patients presented with acute thrombocytopenia and thrombosis, primarily cerebral venous thrombosis, and 1 patient presented with isolated thrombocytopenia and a hemorrhagic phenotype. All the patients had low or normal fibrinogen levels and elevated d-dimer levels at presentation. No evidence of thrombophilia or causative precipitants was identified. Testing for antibodies to platelet factor 4 (PF4) was positive in 21 patients, negative in 1 patient, and equivocal in 1 patient. The authors recommend that treatment with platelet transfusions be avoided because of the risk of progression in thrombotic symptoms and that the administration of a nonheparin anticoagulant agent and intravenous immune globulin be considered for the first occurrence of these symptoms.
The Transplantation Society
740 Notre-Dame Ouest
Montréal, QC, H3C 3X6